Anticoagulant & Antiplatelet Agents

EpiMed Laboratory   →  Research   →  Small Molecules Library related to COVID-19   →  Anticoagulant & Antiplatelet Agents
  • Compound Rivaroxaban
  • Class Anticoagulant & Antiplatelet Agents
  • Human Studies Yes
  • FDA Approved Yes

Rivaroxaban: an anticoagulant that may reduce thrombotic events, hospitalisation, and death in COVID-19 patients.

RELATED PROJECTS